


Trial design: Patients undergoing PCI were randomized to dual antiplatelet therapy (DAPT) aspirin/ticagrelor for 1 month, followed by ticagrelor for 23 months (n = 7,980) vs. DAPT for 12 months, followed by aspirin for 12 months (n = 7,988).



RESULTS

- All-cause mortality or MI: 3.8% of the experimental group vs. 4.4% of the control group ($p = 0.073$)
- All-cause mortality: 2.8% of the experimental group vs. 3.2% of the control group ($p = 0.18$)
- MI: 1.0% of the experimental group vs. 1.3% of the control group ($p = 0.14$)

CONCLUSIONS

- Among patients who underwent PCI with a biolimus-eluting stent, ticagrelor monotherapy for 23 months after 1 month of DAPT was not superior to aspirin monotherapy for 12 months after 12 months of DAPT

Vranckx P, et al. Lancet 2018;Aug 27:[Epub]



AMERICAN
COLLEGE of
CARDIOLOGY®